Growth-stage investor and operator with crossover experience in venture and strategic corporate finance, Jennifer Lutz brings portfolio construction and board-level operational support to technology and healthcare companies. Formerly involved in M&A and corporate development roles, focuses on scaling revenue models, go‑to‑market execution and governance for founder-led businesses. Active in deal sourcing, diligence and value‑creation initiatives; engages with limited partners and co-investors on growth equity and late‑stage venture mandates.
Growth-stage investor and operator with crossover experience in venture and strategic corporate finance, Jennifer Lutz brings portfolio construction and board-level operational support to technology and healthcare companies. Formerly involved in M&A and corporate development roles, focuses on scaling revenue models, go‑to‑market execution and governance for founder-led businesses. Active in deal sourcing, diligence and value‑creation initiatives; engages with limited partners and co-investors on growth equity and late‑stage venture mandates.
Growth-stage investor and operator who blends venture agility with corporate finance rigor to back scaling technology and healthcare companies. Prefers late‑stage growth equity and crossover deals, underwriting durable revenue models, repeatable go‑to‑market engines and founder-led governance. Capital allocation favors concentrated, board‑level positions where active diligence, operational playbooks and LP/co‑investor syndication accelerate commercialization and de‑risk path to profitable scale.
Growth-stage investor and operator who blends venture agility with corporate finance rigor to back scaling technology and healthcare companies. Prefers late‑stage growth equity and crossover deals, underwriting durable revenue models, repeatable go‑to‑market engines and founder-led governance. Capital allocation favors concentrated, board‑level positions where active diligence, operational playbooks and LP/co‑investor syndication accelerate commercialization and de‑risk path to profitable scale.
| Trades 870 | Longs Won 678/870 77% | Profit Factor 45.03 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $305,978.09 |
| Average Win $89,505.81 | Best Trade (Jun 15) $7.33M | Sharpe Ratio -11.89 |
| Average Loss -$7,018.41 | Worst Trade (Mar 31) -$183,354.32 | Z-Score 12.46 (100%) |
| Commissions $0 | Avg. Trade Length 11m 2w 2d | Expectancy $68,203.92 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 33,333 | 30,000 | 26,667 | 23,333 | 20,000 | 16,667 | 13,333 | 10,000 | 6,667 | 3,333 |